logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Treatment of Helicobacter pylori : where are we now ? What are the kev questions ?

    Article - En anglais

    Over the 14 years since Helicobacter pylori came to the attention of the medical community, we have reached the position that the organism is generally believed to be a serious pathogen.

    It causes a chronic infection with complications that include gastric and duodenal ulcer, gastric mucosa-associated lymphoid tissue lymphoma and gastric cancer.

    It is therefore an important cause of morbidity and mortality.

    We still do not have a perfect treatment for the infection, but enormous strides have been made since its discovery and acceptable treatments are now available.

    The best of these are the acid pump inhibitor-and ranitidine bismuth citrate-based triple therapies that provide 85-95% eradication in most studies.

    Better treatments and vaccination programmes may become available now that the Helicobacter genome has been decoded, raising the possibility of'designer'antibiotics and vaccines.

    In the meantime, the current key questions are : How can our current therapies be improved ?

    Who should be treated ?

    What, if any, are the potential risks of widespread H. pylori eradication ?

    And how is the organism transmitted ?

    Without doubt, many of these questions will be addressed in the succeeding years.

    The papers presented in these proceedings represent an up-to-date analysis (much of it based on new data) by recognized experts.

    The views expressed are often provocative, but are backed by scientific data.

    Mots-clés Pascal : Gastrite, Epidémiologie, Chimiothérapie, Helicobacter pylori, Spirillaceae, Spirillales, Bactérie, Historique, Critère décision, Antibiotique, Association médicamenteuse, Forme clinique, Oméprazole, Ranitidine, Article synthèse, Eradication, Homme, Questionnaire, Benzimidazole dérivé, Appareil digestif pathologie, Estomac pathologie, Bactériose, Infection, Antisécrétoire, Antiulcéreux, Inhibiteur enzyme

    Mots-clés Pascal anglais : Gastritis, Epidemiology, Chemotherapy, Helicobacter pylori, Spirillaceae, Spirillales, Bacteria, Case history, Decision criterion, Antibiotic, Drug combination, Clinical form, Omeprazole, Ranitidine, Review, Eradication, Human, Questionnaire, Benzimidazole derivatives, Digestive diseases, Gastric disease, Bacteriosis, Infection, Antisecretory agent, Antiulcer agent, Enzyme inhibitor

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0495955

    Code Inist : 002B05B02F. Création : 22/03/2000.